December 9-11, 2011
Hilton New York
New York City
Program Director(s): Valentin Fuster, M.D., Ph.D., M.A.C.C.
 |
Learning Pathway: General Cardiology: Hypertension, Lipids and Prevention |
ACCF assesses conflict of interest (COI) with its faculty, planners, managers, staff and other individuals who are in a position to control the content of CME/CNE-credited activities. All relevant potential conflicts of interest that are identified are thoroughly vetted through a process that includes course directors and appropriate peer review by education committee chairs/members and/or peer review of content by independent, non-ACC-affiliated clinicians, for fair balance, scientific objectivity and validity, and patient care and safety recommendations. Refer to the links below for committee member disclosures and program faculty disclosures. Please note ACCF staff involved with this program have nothing to disclose.
ACC Live Programs Committee & Staff Disclosures
44th Annual New York Cardiovascular Symposium Disclosures
AGENDA
Friday, December 9
7:15 a.m. |
Jack Lewin, MD, FACC
Chief Executive Officer
American College of Cardiology David R. Holmes Jr., MD, FACC
President
American College of Cardiology Andrew Van Tosh, MD, FACC
President, New York State Chapter
American College of Cardiology
|
Coronary Artery Disease - Challenges in 2011
Session I: New Discoveries in Athero-thrombogenesis, Technologies and Agents
Dr. Virmani, Presiding |
7:30 a.m. |
Prediction of Six Upcoming Clinical Trends for the Decade, Based in Three Evolving Tools: Imaging, Genetics and Cell Regeneration
Dr. Fuster
|
8:00 a.m. |
Endothelium, Opening Door for Disease vs. Closing Door for Health: New Insights Into a Battle of Injury by Risk Factors vs. Cell Regeneration
Dr. Shah
|
8:25 a.m. |
Adventitia Vasa Vasorum and Inflammation: A War in Progress of Defense vs. Betrayal
Dr. Virmani
|
Session II: Acute Coronary Syndromes
Dr. Holmes, Presiding |
| 9:40 a.m. |
STEMI and NON-STEMI: Clock Time Therapy Challenges
The Ambulance, Intervention Stabilization
Dr. Holmes
|
| 10:00 a.m. |
STEMI: The Golden First Two Hours: Evolving Therapies Targeted at Myocardial Demand
Dr. Ibanez
|
| 10:20 a.m. |
Antithrombotic Progress — Evolving Oral Agents:
ADP Inhibitors, Fr Xa Inhibitors, Thrombin Receptor Blockers
Dr. Bhatt
|
| 10:40 a.m. |
Pharmacogenomics of Clopidogrel, Coumadin and Statins:
A So-called “Personalized Medicine”, But Where Is the Data? A View from a Trialist and Guideland’s Expert
Dr. Sabatine A View from a Pioneer in the Field
Dr. Hulot
|
| 11:10 p.m. |
Need for New Antithrombotic or Combinations?
Role of IT and Stakeholders (FDA, NHLBI, Industry)
Dr. Califf
|
Session III: Chronic Coronary and Systemic Arterial Disease
Dr. O'Gara, Presiding |
| 1:15 p.m. |
Athero-thrombosis as a Silent Systemic Disease — The HRP Study: Can Early Detection by Imaging Trigger a Change in Lifestyle?
Dr. Fuster
|
| 1:35 p.m. |
Athero-thrombosis as a Symptomatic Complex CAD and/or CVD: Similar Management Based on Anatomy, Flow and Co-morbidities
Dr. Fuster |
| 1:55 p.m. |
Peripheral Vascular Disease Below the Diaphragm:
Can a Medical/Interventional/Surgical Team Work Together?
Dr. Creager
|
| 2:15 p.m. |
Refractory Angina/Ischemia/Dyspnea in the Elderly:
Evolving Non-interventional Challenges
Dr. O’Gara
|
Session IV: Trends and Challenges of Prevention
Dr. Smith, Presiding |
| 3:25 p.m. |
Lipids and Evolving Approaches: Further Lowering of LDL-C and Targeting HDL-C?
Dr. Smith
|
| 3:50 p.m. |
Hypertension and Evolving Approaches:
From Population Salt Reduction to Personalized Treatment Targets
Dr. Aronow
|
| 4:15 p.m. |
Diabetes and Evolving Approaches: What Are the Contemporary Targets and How to Achieve Them?
Dr. McGuire
|
Saturday, December 10Cardio-pulmonary and Electrical Failure 2011
Session V: Systolic Heart Failure and Basis for Management
Dr. Wilkoff, Presiding |
7:00 a.m. |
Evolving Diagnostic and Prognostic Imaging (MR, CT) of the Various Cardiomyopathies: Myocarditis, Dilated, Infiltrative (Amyloid, Sarcoid), Hypertrophic, Noncompaction
Dr. Sanz |
7:25 a.m. |
Biomarker vs. Clinically Guided Heart Failure Care:
Systolic vs. Diastolic Dysfunction — Where Are the Gains?
Dr. Yancy |
7:45 a.m. |
Evolving Role of Cardiac Resynchronization in Cardiac Failure: Systolic Dysfunction, Diastolic Dysfunction, Mitral Regurgitation
Dr. Wilkoff |
| 8:05 a.m. |
Destination LVADs: A Rapidly-evolving Alternative to Heart Transplantation
Dr. Pinney
|
| 8:25 a.m. |
Trends in Length of Stay, Economics and Tentative Solutions in 2011
Dr. Califf
|
| 8:45 a.m. |
State-of-the-Art Management of Pulmonary Hypertension:
Based on an Understanding of the Various Etiologies
Dr. Oudiz
|
Session VI: Rhythm Disorders, Contemporary and Future Topics of Focus
Dr. Wilber, Presiding |
| 10:10 a.m. |
Integrating the Continuum of Science — Heart Failure and Sudden Death: An Evolving Challenge for the Elderly
Dr. Albert
|
| 10:30 a.m. |
Managing Ventricular Tachycardia:
Catheter Ablation and Beyond, Survival Free from ICD Therapy
Dr. Reddy
|
| 10:50 a.m. |
State-of-the-Art and Evolving Understanding of Atrial Fibrillation: Approach to Quality of Life (Rate/Rhythm and ANSD) and Clots
Dr. Fuster
|
| 11:15 a.m. |
Catheter Ablation in Atrial Fibrillation:
When, How, Present Data and Future Expectations
Dr. Wilber
|
Valvular Heart Disease and Aorta — Challenges in 2011
Session VII: Management of Aortic Valve Disease, IHSS and Aorta
Dr. O’Gara, Presiding |
| 1:00 p.m. |
Asymptomatic Severe AS (AVA< 0.75 cm2 or AVVel > 4.5 m/s) and LVH
Is It Time for Operation?
Dr. O’Gara
|
| 1:20 p.m. |
The Best Aortic Prosthetic Valve Choice for a 45-year-old:
Mechanic? Pericardial (TAVI Later if Degenerates)? Ross Procedure?
Dr. Stelzer
|
| 1:40 p.m. |
The Best Procedure of Choice for a 70- to 80-year-old?
Evolving Approaches to TAVI, Including Stroke Prevention
The Interventionalist Perspective
Dr. Leon
The Surgeon Perspective
Dr. Adams
|
| 2:10 p.m. |
Present Understanding/Management of HCM and Non-compaction LV: Systolic and Diastolic Pharmacological Approach, Antithrombotic?
IHSS — When Septal Reduction (Alcohol, Myectomy)? AICD?
Dr. Maron
|
| 2:35 p.m. |
Asymptomatic or Symptomatic Severe AR:
It’s Never Too Early or Too Late for AVR
Dr. O'Gara
|
| 2:55 p.m. |
The Dilated Aorta and Complicating Dissection:
New Understanding of the Basic Biology and Evolving Management
Dr. Fuster
|
Session VIII: Management of Mitral Regurgitation
Dr. O'Gara, Presiding |
| 3:55 p.m. |
It May Be Too Early or Too Late for Surgery in Severe
Mitral Regurgitation
Dr. O’Gara
|
| 4:15 p.m. |
What A Cardiologist Needs to Know About MR in 2012
Dr. Adams
|
| 4:35 p.m. |
Future of Percutaneous Devices for Mitral Regurgitation:
MitraClip? Coronary Sinus? Percutaneous Remodeling or MVR?
Dr. Feldman
|